• 1
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24:75864.
  • 2
    Scadding GK, Durham SR, Mirakian R et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38:1942.
  • 3
    Smith H. Asthma, inflammation, eosinophils and bronchial hyperresponsiveness. Clin Exp Allergy 1992; 22:18797.
  • 4
    Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:43440.
  • 5
    Keles N. Treatment of allergic rhinitis during pregnancy. Am J Rhinol 2004; 18:238.
  • 6
    Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 (Suppl. 82):120.
  • 7
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007: CD001936.
  • 8
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:31925.
  • 9
    Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33:107682.
  • 10
    Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988; 18:5018.
  • 11
    Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990; 86:292305.
  • 12
    Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol 1997; 7:907.
  • 13
    Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995; 50:92530.
  • 14
    Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005; 15:916.
  • 15
    Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:116272.
  • 16
    Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:102241.
  • 17
    Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113:6439.
  • 18
    Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010; 126:9429.
  • 19
    Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003: CD002893.
  • 20
    Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 12:CD002893.
  • 21
    Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:1418.
  • 22
    Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007; 62:95861.
  • 23
    Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol 2009; 124:15761.
  • 24
    Durham SR. Sublingual immunotherapy: what have we learnt from the ‘big trials’? Curr Opin Allergy Clin Immunol 2008; 8:57784.
  • 25
    Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 2009; 9:16876.
  • 26
    Larenas-Linnemann D. Sublingual immunotherapy in children: more optimism today. Pediatr Allergy Immunol 2009; 20:399400.
  • 27
    Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86):8160.
  • 28
    Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:46875.
  • 29
    Des Roches A., Paradis L, Knani J et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:4303.
  • 30
    Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:1318.e7.
  • 31
    Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60:8017.
  • 32
    Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498505.
  • 33
    Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009; 64:1394401.
  • 34
    Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978; 61:3707.
  • 35
    Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med 1965; 273:6759.
  • 36
    Adkinson NF Jr, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336:32431.
  • 37
    Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martín-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Clin Exp Allergy 2005; 35:7528.
  • 38
    Marogna M, Spadolini I, Massolo A et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007; 98:27480.
  • 39
    Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124:1506.
  • 40
    Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002; 14:71827.
  • 41
    Grier TJ, LeFevre DM, Duncan EA, Esch RE. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. Ann Allergy Asthma Immunol 2007; 99:15160.
  • 42
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:55862.
  • 43
    Hedlin G, Heilborn H, Lilja G et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96:87985.
  • 44
    Nanda A, O'connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114:133944.
  • 45
    Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:8607.
  • 46
    Arvidsson MB, Lowhagen O, Rak S. Early and late phase asthmatic response in lower airways of cat-allergic asthmatic patients – a comparison between experimental and environmental allergen challenge. Allergy 2007; 62:48894.
  • 47
    Desensitising vaccines: an allergist's view. Br Med J (Clin Res Ed) 1986; 293:116970.
  • 48
    British Thoracic Society (BTS). Guideline on the management of asthma. Thorax 2008; 63 (Suppl. 4):iv1121.
  • 49
    Javeed N, Javeed H, Javeed S, Moussa G, Wong P, Rezai F. Refractory anaphylactoid shock potentiated by beta-blockers. Cathet Cardiovasc Diagn 1996; 39:3834.
  • 50
    Kivity S, Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient treated with beta-blocker and Ca blocker. J Allergy Clin Immunol 1990; 85:66970.
  • 51
    Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 1991; 115:2706.
  • 52
    Newman BR, Schultz LK. Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride. Ann Allergy 1981; 47:357.
  • 53
    Blaiss MS. Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol 2003; 90:1622.
  • 54
    Ibanez MD, Kaiser F, Knecht R et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007; 18:51622.
  • 55
    Finegold I. Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc 2007; 28:698705.
  • 56
    Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:2516.
  • 57
    Niggemann B, Jacobsen L, Dreborg S et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61:8559.
  • 58
    Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:9438.
  • 59
    Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:27480.
  • 60
    Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986; 41:2719.
  • 61
    Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:16773.
  • 62
    Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:1606.
  • 63
    Halken S, Agertoft L, Seidenberg J et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010; 21:9706.
  • 64
    Des Roches A., Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:4503.
  • 65
    Pajno GB, Barberio G, De LF, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:13927.
  • 66
    Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:8517.
  • 67
    Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000; 55:11427.
  • 68
    Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J. Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009; 148:1619.
  • 69
    Serrano P, Justicia JL, Sanchez C et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol 2009; 102:24752.
  • 70
    Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009; 39:4018.
  • 71
    Ariano R, Incorvaia C, La GS et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 2009; 25:1037.
  • 72
    Seidenberg J, Pajno GB, Bauer CP, La GS, Sieber J. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol 2009; 19:12531.
  • 73
    Ma S, Sicherer SH, Nowak-Wegrzyn A. A survey on the management of pollen-food allergy syndrome in allergy practices. J Allergy Clin Immunol 2003; 112:7848.
  • 74
    Kelso JM, Jones RT, Tellez R, Yunginger JW. Oral allergy syndrome successfully treated with pollen immunotherapy. Ann Allergy Asthma Immunol 1995; 74:3916.
  • 75
    Baumann K, Roessler F, Müllner G, Pichler WJ, Helbling A. Effect of the specific, subcutaneous immunotherapy with pollen extracts on the pollen-associated food allergy. A retrospective analysis on 72 patients. Allergologie 2002; 25:32632.
  • 76
    Modrzynski M, Zawisza E, Rapiejko P, Przybylski G. Specific-pollen immunotherapy in the treatment of oral allergy syndrome in patients with tree pollen hypersensitivity. Przegl Lek 2002; 59:100710.
  • 77
    Asero R. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 1998; 28:136873.
  • 78
    Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004; 59:12726.
  • 79
    Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK, Malling HJ. Food allergy to apple and specific immunotherapy with birch pollen. Mol Nutr Food Res 2004; 48:4418.
  • 80
    Czarnecka-Operacz M, Jenerowicz D, Silny W. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy. Acta Dermatovenerol Croat 2008; 16:1924.
  • 81
    Modrzynski M, Zawisza E. Possible induction of oral allergy syndrome during specific immunotherapy in patients sensitive to tree pollen. Med Sci Monit 2005; 11:CR3515.
  • 82
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:8029.
  • 83
    Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:133845.
  • 84
    Allergen immunotherapy: therapeutic vaccines for allergic dieseases. Allergy 1998; 53 (Suppl. 44):142.
  • 85
    Council of Europe. 2001; Strasbourg. European Pharmacopoeia; European Series 50. Strasbourgh, France: Council of Europe.
  • 86
    Larsen JN, Houghton CG, Lowenstein H, Lombardero M. Manufacturing and standardizing allergen extracts in Europe. Clin Allergy Immunol 2004; 18:43355.
  • 87
    Lowenstein H. Purification and characterization of allergens. Summing up. Allergy 1980; 35:2101.
  • 88
    Spangfort MD, Larsen JN. Standardization of allergen-specific immunotherapy vaccines. Immunol Allergy Clin North Am 2006; 26:191206.
  • 89
    Chapman MD, Ferreira F, Villalba M et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122:8829.
  • 90
    Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:56974.
  • 91
    Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:95160.
  • 92
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:60813.
  • 93
    Malling HJ, Weeke B. Immunotherapy (Position Paper). Allergy 1993; 48:935.
  • 94
    Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996; 97:120713.
  • 95
    Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol 2004; 113:112936.
  • 96
    Andre C, Fadel R. Anaphylaxis caused by allergen sublingual immunotherapy? Allergy 2007; 62:12201.
  • 97
    Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235.
  • 98
    Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62:5678.
  • 99
    de Groot H., Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:9634.
  • 100
    Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:56571.
  • 101
    Cox LS, Larenas LD, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:102135.
  • 102
    Lombardi C, Gargioni S, Cottini M, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008; 63:3756.
  • 103
    Passalacqua G, Pawankar R, Baena-Cagnani CE, Canonica GW. Sublingual immunotherapy: where do we stand? Present and future. Curr Opin Allergy Clin Immunol 2009; 9:13.
  • 104
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:412.
  • 105
    Radulovic S, Calderon M, Wilson S, Durham S. Sublingual immunotherapy for allergic rhinitis: an updated Cochrane systematic review and meta-analysis. Allergy 2007; 62 (Suppl. 83):263; Abstract.
  • 106
    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119:88191.
  • 107
    Rodriguez-Perez N, mbriz-Moreno MJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:30410.
  • 108
    Drummond M, Dubois D, Garattini L et al. Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 1999; 2:32332.
  • 109
    Sculpher M. The use of quality-adjusted life-years in cost-effectiveness studies. Allergy 2006; 61:52730.
  • 110
    Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. Clin Exp Allergy 2007; 37:7729.
  • 111
    Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007; 101:188594.
  • 112
    Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008; 63:16249.
  • 113
    Hankin CS, Cox L, Lang D et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:22732.
  • 114
    Berto P, Frati F, Incorvaia C et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 2008; 24:2616.
  • 115
    Ariano R, Berto P, Tracci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006; 27:15963.
  • 116
    Berto P, Bassi M, Incorvaia C et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol 2005; 37:3038.
  • 117
    Berto P, Passalacqua G, Crimi N et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006; 97:61521.
  • 118
    Omnes LF, Bousquet J, Scheinmann P et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol 2007; 39:14856.
  • 119
    Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2008; 100:4829.
  • 120
    Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S155.
  • 121
    Gawchik SM, Saccar CL. Pollinex quattro tree: allergy vaccine. Expert Opin Biol Ther 2009; 9:37782.
  • 122
    Bowen T, Greenbaum J, Charbonneau Y et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93:42530.
  • 123
    Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498504.
  • 124
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994; 4:30514.
  • 125
    Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998; 53:4938.
  • 126
    Lima MT, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:50714.
  • 127
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993; 92:22936.
  • 128
    Passalacqua G, Albano M, Riccio A et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:9648.
  • 129
    Pradalier A, Basset D, Claudel A et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54:81928.
  • 130
    Sanchez PA, Schamann F, Garcia JA. Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol (Madr) 2001; 29:605.
  • 131
    Tonnel AB, Scherpereel A, Douay B et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59:4917.
  • 132
    Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:66272.
  • 133
    Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 2003; 13:1706.
  • 134
    Lombardi C, Gargioni S, Venturi S, Zoccali P, Canonica GW, Passalacqua G. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Investig Allergol Clin Immunol 2001; 11:415.
  • 135
    Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:5128.
  • 136
    BSACI Working Party. Position paper on allergen immunotherapy. Report of a BSACI working party. January-October 1992. Clin Exp Allergy 1993; 23:144.
  • 137
    James LK, Shamji MH, Walker SM et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:50916.
  • 138
    La Rosa M., Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:42532.
  • 139
    Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114:8317.
  • 140
    Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergol Immunopathol (Madr) 1994; 22:20916.
  • 141
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990; 18:27784.
  • 142
    Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:102534.
  • 143
    Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl. 2):1467782.
  • 144
    Shamji MH, Wilcock LK, Wachholz PA et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317:719.
  • 145
    Durham SR, Varney VA, Gaga M et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999; 29:14906.
  • 146
    Gozalo F, Martin S, Rico P, Alvarez E, Cortes C. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy. Allergol Immunopathol (Madr) 1997; 25:21927.
  • 147
    Ippoliti F, De SW, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:21621.
  • 148
    Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:62932.
  • 149
    Marcucci F, Sensi L, Frati F et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 2003; 58:65762.
  • 150
    Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:32529.
  • 151
    Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:11205.
  • 152
    Fanta C, Bohle B, Hirt W et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:21824.
  • 153
    Cirla AM, Cirla PE, Parmiani S, Pecora S. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. Allergol Immunopathol (Madr) 2003; 31:3143.
  • 154
    Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82:47080.
  • 155
    Crimi E, Voltolini S, Troise C et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991; 87:7218.
  • 156
    Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma – a double-blind study. J Investig Allergol Clin Immunol 1992; 2:5967.
  • 157
    Valovirta E, Passalacqua G, Canonica WG. Non-injection routes for immunotherapy of allergic diseases. Clin Allergy Immunol 2004; 18:60723.
  • 158
    Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:43748.
  • 159
    Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008; 105:1790812.
  • 160
    Senti G, Graf N, Haug S et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124:9971002.
  • 161
    Klunker S, Saggar LR, Seyfert-Margolis V et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:68895.
  • 162
    Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004; 34:13738.
  • 163
    Garcia-Patos V, Pujol RM, Alomar A et al. Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol 1995; 131:14214.
  • 164
    Jones SK, Lovell CR, Peachey RD. Delayed onset of inflammatory nodules following hay fever desensitization injections. Clin Exp Dermatol 1988; 13:3768.
  • 165
    Netterlid E, Hindsen M, Bjork J et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis 2009; 60:419.
  • 166
    Baldrick P, Richardson D, Woroniecki SR, Lees B. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J Appl Toxicol 2007; 27:399409.
  • 167
    Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005; 60:67884.
  • 168
    Kussebi F, Karamloo F, Rhyner C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 115:3239.
  • 169
    Karamloo F, Schmid-Grendelmeier P, Kussebi F et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005; 35:326876.
  • 170
    Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22:1758.
  • 171
    Larche M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006; 18:74550.
  • 172
    Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:144555.
  • 173
    Kundig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:14706.
  • 174
    Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:13440.
  • 175
    Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008; 38:14008.
  • 176
    Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 2009; 39:42936.
  • 177
    Schmid-Grendelmeier P. Recombinant allergens. For routine use or still only science? Hautarzt 2010; 61:94653.
  • 178
    Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:21141.